The U.S. veterinary oncology diagnostics market size was valued at USD 992.64 billion in 2024. The market is projected to grow from USD 1,074.04 billion in 2025 to USD 2,228.87 billion by 2034, exhibiting a CAGR of 8.4% during 2025–2034.
Cancer is a leading cause of death in older pets, with studies indicating that 47% of dogs over the age of 10 and 32% of cats succumb to the disease . This alarming statistic has spurred demand for advanced diagnostic tools and services, prompting veterinary clinics and diagnostic laboratories to adopt cutting-edge technologies for early detection and treatment planning.
Market Segmentation
The U.S. veterinary oncology diagnostics market is segmented based on animal type, diagnostic test type, cancer type, and end-use application.Polaris
- Animal Type:
- Canine: Currently holds the largest market share due to the higher prevalence of cancer in dogs and the availability of a wide range of diagnostic products tailored for canine oncology.
- Feline: Anticipated to exhibit the highest growth rate from 2025 to 2030, driven by increasing awareness among cat owners regarding the susceptibility of felines to various forms of cancer.
- Others: Includes equine and exotic pets, contributing to a smaller yet growing segment.
- Diagnostic Test Type:
- Imaging: Dominates the market due to the widespread use of radiography, ultrasound, CT scans, and MRI in the initial detection and staging of cancers in animals.
- Blood Tests: Increasingly utilized for screening and monitoring treatment responses.
- Biopsy: Provides definitive diagnosis through histopathological examination.
- Genome Testing: Emerging as a valuable tool for personalized treatment planning.
- Endoscopy: Used for direct visualization and biopsy of internal structures.
- Urinalysis: Assists in detecting cancers affecting the urinary tract.
- Cancer Type:
- Lymphoma: The most common cancer in dogs, leading to a significant demand for diagnostic services .
- Sarcomas: Anticipated to exhibit the highest growth rate, driven by advancements in diagnostic imaging and molecular techniques .
- Skin Cancers: Emerging as the fastest-growing segment, attributed to the increasing incidence of skin tumors in companion animals .
- Others: Includes cancers affecting organs such as the liver, lungs, and gastrointestinal tract.
- End-Use Application:
- Reference Laboratories: Hold the largest market share, as specialized diagnostic testing, particularly advanced molecular diagnostics and complex biomarker analyses, are often outsourced to these facilities .
- Veterinary Hospitals & Clinics: Increasingly adopting in-house diagnostic capabilities to provide timely and comprehensive care.
Read More @ https://www.polarismarketresearch.com/industry-analysis/us-veterinary-oncology-diagnostics-market
Regional Analysis
The U.S. veterinary oncology diagnostics market is characterized by regional variations in pet ownership patterns, healthcare infrastructure, and access to specialized veterinary services.
- Northeast: High concentration of veterinary oncology specialists and advanced diagnostic facilities, leading to early adoption of innovative diagnostic tools.
- West Coast: Significant demand for personalized and holistic veterinary care, driving the adoption of advanced diagnostic services.
- Midwest: Growing awareness and access to veterinary oncology services, contributing to market expansion.
- South: Increasing pet ownership and veterinary care expenditure, fostering market growth.
Overall, the U.S. market exhibits a trend toward regional specialization, with certain areas leading in specific diagnostic modalities and treatment approaches.
Key Companies
Several prominent players are actively contributing to the growth of the U.S. veterinary oncology diagnostics market:
- IDEXX Laboratories, Inc.: A leader in veterinary diagnostics, IDEXX offers a range of diagnostic tests and services, including the upcoming Cancer Dx screening test for canine lymphoma .
- Zoetis Inc.: Provides a comprehensive portfolio of veterinary oncology diagnostics and therapeutics.
- Boehringer Ingelheim International GmbH: Develops innovative diagnostics and treatments for veterinary oncology.
- Zenoaq: Specializes in veterinary oncology diagnostics and therapeutics.
- Morphogenesis, Inc.: Focuses on immunotherapy and diagnostics for veterinary oncology.
These companies are at the forefront of developing and delivering advanced diagnostic solutions, contributing to improved outcomes in veterinary oncology.
Conclusion
The U.S. veterinary oncology diagnostics market is poised for substantial growth, driven by increasing pet cancer awareness, advancements in diagnostic technologies, and a growing emphasis on early detection and personalized treatment. As the market expands, stakeholders across the veterinary healthcare ecosystem are focusing on innovation, accessibility, and collaboration to enhance the quality of care for companion animals.
More Trending Latest Reports By Polaris Market Research:
Space Debris Monitoring and Removal Market
Education Technology SaaS Tools Market
Growing Concerns over Food Waste Globally to Boost Market
Explosion-Proof Light Fixtures Market
North America SGLT2 Inhibitors Market
In-Vehicle Infotainment Market
